Abstract
We report an international external quality control scheme on neurotransmitter metabolites in cerebrospinal fluid (CSF). The neurotransmitter metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are analysed to diagnose inborn errors of neurotransmitter metabolism. HVA is the catabolite of dopamine; 5-HIAA is the catabolite of serotonin; and MHPG is the catabolite of noradrenaline. In the first phase, 12 laboratories from six countries participated in this special quality control scheme to define the present state of the art and achieve harmonization in analytical outcome and interpretation. In the second part, recoveries, dilutions and methods for sample preparation were compared. The results of 3 of 12 laboratories were excluded because of unacceptable intralaboratory coefficients of variations (CV) for HVA and/or 5-HIAA. The inter- and intralaboratory CVs, the linearity and the recovery were acceptable for the other laboratories for both parameters.Unacceptable differences in the reference ranges between laboratories, leading to differences in interpretation of the results, became obvious. There was a significant improvement of the interlaboratory CV for HVA after standardization with a calibrator. The reproducibility of MHPG measurement appeared to be adequately established in only two laboratories and recovery was low in all five measuring this metabolite. The quality control scheme is an invaluable tool for controlling the analytical outcome and providing support to laboratories to improve their quality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Blau N (1988) Inborn errors of pterin metabolism. Annu Rev Nutr 8: 185-209.
Blau N, Hoffmann GF (1998) Differential diagnosis of disorders of biogenic amines metabolism. Eur J Pediatr Neurol 2: 219-220.
Bräutigam C, Wevers RA, Jansen RJT, et al (1998) Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 44: 1897-1904.
Brunner HG, Nelen M, Breakefield XO (1993) Abnormal behaviour associated with a point mutation in the structural gene for monoamine oxidase A. Science 262: 578-580.
Hoffmann GF, Surtees RAH, Wevers RA (1998) Cerebrospinal fluid investigations for neurometabolic disorders. Neuropediatrics 29: 59-71.
Hyland K (1993) Abnormalities of biogenic amine metabolism. J Inherit Metab Dis 16: 676-690.
Hyland K, Surtees RAH, Rodeck C, Clayton PT (1992). Aromatic l-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42: 1980-1988.
Hyland K, Surtees RAH, Heales SJR, Bowron A, Howells DW, Smith I (1993) Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 34: 10-14.
Korenke GC, Christen H-J, Hyland K, Hunneman DH, Hanefeld F (1997) Aromatic l-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur J Pediatr Neurol 2/3: 67-71.
Man in't Veld AJ, Boomsma F, Moleman P, Schalekamp MADH (1987) Congenital dopamine-beta-hydroxylase deficiency. Lancet 1: 183-188.
Wevers RA, de Rijk-van Andel JF, Bräutigam C, et al (1999) A review of biochemical and molecularg enetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC) [Review]. J Inherit Metab Dis 22: 364-373.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bräutigam, C., Weykamp, C., Hoffmann, G.F. et al. Neurotransmitter metabolites in CSF: An external quality control scheme. J Inherit Metab Dis 25, 287–298 (2002). https://doi.org/10.1023/A:1016550324235
Issue Date:
DOI: https://doi.org/10.1023/A:1016550324235